TDP-43 (TAR DNA-binding protein 43) has been identified as a key protein of ubiquitinated inclusions in brains of patients with ALS (amyotrophic lateral sclerosis) or FTLD (frontotemporal lobar degeneration), defining a new pathological disease spectrum. Recently, coding mutations have been identified in the TDP-43 gene (TARDBP), which further confirmed the pathogenic nature of the protein. Today, several animal models have been generated to gain more insight into the disease-causing pathways of the FTLD/ALS spectrum. This mini-review summarizes the current status of TDP-43 models, with a focus on mutant TDP-43.
The role of mutant TAR DNA-binding protein 43 in amyotrophic lateral sclerosis and frontotemporal lobar degeneration Introduction ALS (amyotrophic lateral sclerosis), also known as Lou Gehrig's disease, is considered the most common adultonset MND (motor neuron disease) with severe impact on the quality of life of patients. It is a progressive disorder that involves selective degeneration of both upper and lower motor neurons situated in the cortex, brainstem and anterior horn of the spinal cord. Disease progression is marked by muscle atrophy, spasticity and weakness. Paralysis of the respiratory muscles is usually fatal within 1-5 years after disease onset. Up to 10% of ALS patients have fALS (familial ALS) or conversely the majority of ALS patients (90%) are considered to be sALS (sporadic ALS) because they lack a familial disease history [1] .
The identification of mutations in SOD1 (encoding superoxide dismutase 1) has fuelled ALS research during the last 15 years and has provided several important insight into the pathobiology of SOD1-associated ALS [2] . Multiple disease processes have been identified ranging from mitochondrial dysfunction, compromised axonal transport to excitotoxicity (for review see [3] ). Today, mutant SOD1 is considered to be the most common genetic cause of ALS, accounting for ∼20% of fALS and ∼1% of sporadic cases.
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cortical dementia and is characterized by a progressive neuronal loss in the frontal and/or temporal lobes. Also, ∼15% of FTLD patients develop symptoms of MND (FTLD-MND) [4] , indicating that ALS and FTLD are part of a broader disease spectrum [5] .
TDP-43 (TAR DNA-binding protein 43) links ALS and FTLD
A landmark discovery in comprehending ALS and FTLD was made in 2006 with the identification of TDP-43 as the major protein constituent of ubiquitinated inclusions found in affected brain regions in the majority of patients with ALS and FTLD [6, 7] (FTLD-TDP [8] ), providing a molecular link between both neurodegenerative disorders. Additionally, secondary TDP-43 pathology has also been observed in other neurodegenerative brain diseases including Alzheimer's disease and Parkinson's disease [5] . Nonetheless, TDP-43 inclusions were absent in SOD1-ALS, suggesting that different pathomechanisms might underlie both ALS subtypes [9] .
TDP-43 is a ubiquitously expressed 414-amino acid protein encoded by TARDBP on chromosome 1p36.2. The protein is predominantly localized in the nucleus and is highly conserved among different species [10] . As a member of the heterogeneous ribonucleoprotein family, TDP-43 comprises two highly conserved RRMs (RNA-recognition motifs; RRM1 and RRM2) and a glycine-rich C-terminal region, allowing binding to RNA, DNA and proteins [11, 12] . Although detailed knowledge about its cellular processes is still incomplete, evidence is accumulating that TDP-43 is implicated in regulation of transcription and splicing, mRNA stability, microRNA biogenesis and scaffolding for nuclear bodies (for review see [13, 14] ).
Whether TDP-43 dysfunction could contribute to neurodegeneration by a toxic GOF (gain-of-function) or a LOF (loss-of-function) is heavily debated, but a specific pathological signature of TDP-43 is significant as it is absent under physiological conditions. Post-mortem analysis of ALS and FTLD brains revealed abundant TDP-43 positive cytoplasmic and nuclear inclusions in neuronal and glial cells. TDP-43 proteinopathy is further characterized by abnormal TDP-43 modifications including hyperphosphorylation, ubiquitination and proteolytical truncation to generate CTFs (C-terminal fragments) [6, 7] . Surprisingly, the composition of TDP-43 inclusions in ALS patients varies between cortical and spinal cord regions that are mainly composed of CTFs and full-length TDP-43 respectively [15, 16] . During TDP-43 pathogenesis, TDP-43 is redistributed from the nucleus to the cytoplasm (nuclear clearing), suggesting a LOF due to loss of essential nuclear functions. But, it remains unclear as to whether nuclear clearing is the key event in pathogenesis or whether protein aggregation or formation of CTFs is the disease culprit via a GOF of toxic properties. In this respect, it is of note that delocalization and ubiquitination of TDP-43 were reported as being likely to constitute early events, preceding deposition of insoluble inclusion bodies [17] .
TARDBP mutations in the FTLD/ALS spectrum
Accumulation of abnormal protein aggregates is a widespread characteristic seen in several neurodegenerative diseases, and mutations have been identified in the genes encoding the deposited proteins [18, 19] . Consequently, TARDBP was analysed in patients for mutations associated with FTLD and/or ALS. Although initial studies in FTLD patients were negative [20] , autosomal dominant mutations were identified in sALS and fALS patients [21] . This discovery indicated that aberrant TDP-43 is sufficient to trigger neurodegeneration and not just a pathological bystander in the disease cascade [22] . Today, a set of 43 different TARDBP mutations is known (http://www.molgen.ua.ac.be/FTDMutations/) [23] , of which the majority are predicted to be pathogenic and were identified in several unrelated families worldwide (Table 1) . Almost all TARDBP mutations are missense mutations located in exon 6 encoding the C-terminal part of TDP-43. Two exceptions are a truncating mutation Y374X [24] and the D169G mutation in RRM1 [25] . Mutations in TARDBP are rare in ALS because their estimated frequencies are ∼4% in fALS and ∼1.5% in sALS patients [26] .
Since TDP-43 proteinopathy is characteristic in case of all diseases of the FTLD/ALS spectrum, one would also expect mutations in FTLD-MND and pure FTLD patients. However, to date, only three mutations (K263E, N267S and M359V) were identified in patients with pure FTLD (of which N267S was already known to be pathogenic in an ALS patient) [27] [28] [29] , as well as one mutation (G295S) in two patients with FTLD-MND [30] . Nevertheless, these findings illustrate that mutations in TARDBP are not restricted to ALS patients, and that further research is necessary to define the exact contribution of mutations to FTLD-TDP and FTLD-MND.
In addition to pathogenic mutations, a role was also suggested for benign genetic variations in TARDBP. These include missense mutations (D65E and A90V) and mutations in UTRs (untranslated regions) or introns. Although some variants were also detected in control individuals, the majority appeared only in patients and were predicted to influence splicing or act as a genetic risk factor for disease (e.g. A90V; Table 1 ) [31] .
How mutations abolish TDP-43 functions
Available genetic evidence indicates that TDP-43 dysfunction is sufficient to cause FTLD-TDP and ALS. However, how mutant TDP-43 causes neurodegeneration remains enigmatic. Potentially, the C-terminal region of TDP-43 might have a role in disease pathogenesis since it mediates protein-binding and contains most of the disease-related TDP-43 mutations that could abolish protein-protein interactions. Also, several mutations are expected to alter the phosphorylation state of TDP-43 by introducing new phosphorylation sites or increasing phosphorylation of adjacent residues [21, 32] . Thus impaired phosphorylation might be involved in the pathogenesis of TDP-43 proteinopathy.
Since during disease TDP-43 is largely shifted to the cytoplasm in affected cells, one could also hypothesize that TARDBP mutations enhance the susceptibility of TDP-43 to aggregate, leading to nuclear depletion of TDP-43, as shown in mammalian and yeast cell systems [33, 34] . As a result, failure of RNA metabolism in the nucleus could provoke aberrant autoregulation of TDP-43 levels, perturbed microRNA processing or abnormal splice variants [14] . Further support for a pivotal role of aberrant RNA metabolism in disease pathogenesis came from the identification of FUS/TLS (fused in sarcoma/translocated in liposarcoma) as a new pathologic protein in ALS and FTLD [35] . Both the TDP-43 and FUS proteins show striking structural and functional similarities as DNA-/RNA-binding proteins, indicating that common RNA targets might be affected and causing neurodegeneration [26] . Recently, RNA targets of TDP-43 have been identified, which relate to synaptic function, RNA metabolism and neuronal development. Intriguingly, TDP-43 also has the potential to bind RNA encoding proteins involved in FTLD/ALS, including FUS/TLS, progranulin and ataxin [36] .
On the other hand, increased soluble or aggregated forms of TDP-43 or its CTFs in the cytoplasm might result in a toxic GOF. TDP-43 is aggregation prone as the WT (wild-type) protein forms aggregates spontaneously under normal conditions, and its propensity for toxic misfolding is accelerated by ALS-linked mutations [33] . In contrast, TDP-43 accumulation in primary neurons was not a prerequisite for mutant TDP-43 toxicity, while increased cytoplasmic mislocalization of TDP-43 was associated with toxicity. These data indicated that the relocation of mutant TDP-43 to the cytoplasm by itself exhibits a toxic GOF [37] . Although both loss of nuclear functions and gain of cytoplasmic functions are conceivable mechanisms, they are not necessarily mutually exclusive as they may co-occur in disease, implying that the aetiology of ALS could be multifactorial. Alternatively, cytoplasmic TDP-43 accumulations sequester endogenous, nuclear TDP-43, suggesting that a dominant-negative effect might also have a role in the disease process [38] . In order to gain more insight into the function of TDP-43 in vivo, different animal models expressing WT or mutant forms of TDP-43 have been generated.
Mutant TDP-43 modelling
Several animal models have been generated to investigate the pathogenic nature of different TDP-43 mutations. For example, overexpression of the hTDP-43 (human TDP-43) mutations M337V and Q331K in chick embryos resulted in embryonic growth defects and increased apoptosis, supporting a toxic GOF or a dominant-negative effect of mutant TDP-43 [21] . In a Drosophila model, however, the same hTDP-43 mutations attenuated dendritic branching activity compared with WT hTDP-43, reflecting a LOF mechanism [39] . Remarkably, expression of the glycinerich domain without the RRM1 domain did not affect neuronal morphology or function in fruitflies compared with WT hTDP-43. This implies that neurotoxicity requires the N-terminus including the RRM1 motif of TDP-43 [40] . Furthermore, it was also shown that the neurotoxicity depends more on an inherent RNA-binding activity rather than mislocalization and truncation of TDP-43 or the ALSlinked mutation itself [41] . Overexpression of WT and mutant TDP-43 in zebrafish resulted both in a similar motor phenotype consisting of motor axon and swimming deficits, although it was much more pronounced for mutant TDP-43. Furthermore, coexpression of mutant TDP-43 also failed to rescue, unlike WT TDP-43, a similar phenotype caused by TDP-43 knockdown. Together, these data indicate that motor neuron defects and toxicity are caused by simultaneous toxic GOF and LOF mechanisms [42] .
Although fruitflies and fish are powerful and relatively fast tools to investigate pathogenic effects of mutations, rodent models offer a system that is more akin to humans. Several rodent models have been reported on the basis of two mutant forms of hTDP-43, i.e. A315T and M337V [43] [44] [45] . Overexpression of mutant A315T TDP-43 (∼3-fold higher than endogenous TDP-43) under control of the PrP (prion protein) promoter triggered the development of an early motor phenotype with an average survival of 5 months. Ubiquitinated protein aggregates were present in specific populations of cortical and spinal motor neurons, resembling ALS pathology. Surprisingly, TDP-43 was not a component of these aggregates, indicating that altered DNA/RNA-binding, rather than toxic aggregation, is central in the disease mechanism. In addition, TDP-43 CTFs were found before disease onset, pointing to a direct role in neurodegeneration. These results suggest that TARDBP mutations could cause disease by a toxic GOF mechanism [43] . A similar early motor phenotype was observed by expressing high levels of mutant A315T or M337V under the control of the same promoter. Mice occasionally developed intranuclear, ubiquitin-positive inclusions and generated CTFs. Instead, mouse lines with intermediate levels of A315T manifested a slower disease progression and WT overexpressing mice did not show a phenotype [44] . Zhou et al. [45] generated a mutant overexpression rat model driven by a tetracycline regulatory system, as constitutive expression caused postnatal death. Temporal expression of human M337V TDP-43 reproduced an ALS-like phenotype characterized by progressive widespread degeneration of motor neurons and atrophy in skeletal muscles. TDP-43 proteinopathy was recapitulated by the rare formation of TDP-43-positive inclusions, cytoplasmic localization with phosphorylation and fragmentation of the protein. However, the typical ubiquitin-positive inclusions were absent in spinal cords of transgenic rats. We have developed transgenic mice overexpressing the same M337V mutation, resulting in a dosedependent degeneration of specific neurons accompanied by nuclear clearing of TDP-43 and increased ubiquitin immunoreactivity (J. Janssens, G. Kleinberger, H. Wils, G. Joris, I. Cuijt, C. Van Broeckhaven and S. Kumar-Singh, unpublished work). Taken together, the major conclusion that can be drawn from transgenic small model organisms is that both LOF and GOF are possible mechanisms, while in rodent models overexpression of TDP-43 supports a toxic GOF. However, further research is clearly needed to better understand whether nuclear clearing, modification, aggregation of TDP-43 or a combination of all are key elements in neurodegeneration.
TDP-43-overexpressing models
The majority of ALS patients are sporadic cases without TARDBP mutations, implying that WT TDP-43 can also play a central role in the disease cascade. Indeed, different neuronal (Thy1 promoter) and pan-neuronal (PrP promoter) overexpressing mouse models of WT TDP-43 have shown characteristic features of FTLD/ALS pathology, including gait abnormalities and hallmarks of TDP-43 proteinopathy (H. Wils, S. Kumar-Singh and C. Van Broeckhoven, unpublished work). Remarkably, almost all models published today are based on overexpression, while abnormally high TDP-43 levels have not been identified in patients. Although dosage mutations have not been identified, it cannot be excluded that subtle changes in expression can contribute to neurodegeneration. In this context, it is notable that polymorphic genetic variants have been identified within the 3 -UTR of TARDBP that were able to increase TDP-43 mRNA and protein levels. [46] . Besides, using pulse chase experiments, it has been determined that some ALS-linked TDP-43 mutants exhibit longer protein half-lives compared with WT TDP-43, suggesting that abnormal protein stability may lead to an increase of TDP-43 within the cell [47] . One can hypothesize that slight increases of TDP-43 during lifetime could induce neurodegeneration. On the other hand, depletion of TDP-43 is lethal, indicating that TDP-43 is also essential for prenatal development and survival (H. Wils, S. Kumar-Singh and C. Van Broeckhoven, unpublished work). Strict autoregulatory mechanisms are probably involved in maintaining TDP-43 levels since protein expression levels in heterozygous knockout mice are almost similar to nontransgenic mice [14] . On the basis of these studies, it is clear that a tight TDP-43 balance is crucial at least for maintaining neuronal homoeostasis.
The reported models can provide us with novel insights into disease, but it remains difficult to determine whether toxicity is caused by overwhelming the system with TDP-43 or by the mutation itself. In order to faithfully model the pathology of TDP-43 in rodents, it would also be interesting to replicate the expression patterns of TDP-43 by generating a knock-in mouse model for TDP-43. Nevertheless, the currently available models develop important aspects of pathology and might also be useful in testing diseasemodifying compounds or therapeutics for diseases of the FTLD/ALS spectrum.
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